← 返回治疗方案
Oncology

CAR-T Cell Therapy

Revolutionary immunotherapy that reprograms your own immune cells to fight cancer. China offers FDA-approved CAR-T treatments at 60-80% lower cost than the US.

CAR-T Cell Therapy

快速判断

Revolutionary immunotherapy that reprograms your own immune cells to fight cancer. China offers FDA-approved CAR-T treatments at 60-80% lower cost than the US.

主要适应症
B-cell Acute Lymphoblastic Leukemia (ALL) · Diffuse Large B-cell Lymphoma (DLBCL) · Multiple Myeloma
常见治疗阶段
Initial Consultation · Eligibility Assessment

想更快确认下一步?

先做一次免费病例评估,再判断这项治疗是否适合您,以及更适合走哪家医院路径。

OriEast 如何协助您

我们帮助国际家庭比较治疗方案、准备病历,并更顺畅地从信息检索进入预约流程。

  • 协助判断这项治疗是否适合当前病例
  • 匹配更合适的医院、科室与专家路径
  • 协调病例评估与下一步预约建议
  • 在上海就医期间提供语言、陪同与流程支持

您的病历仅会在协调专家评估和预约所需范围内使用。

费用对比

美国
$400,000 - $500,000
中国(OriEast)
$80,000 - $150,000
您的节省
Up to 80%

* 价格为估算值,可能因个人情况而异。请联系我们获取个性化报价。

我们治疗的病症

B-cell Acute Lymphoblastic Leukemia (ALL)
Diffuse Large B-cell Lymphoma (DLBCL)
Multiple Myeloma
Follicular Lymphoma
Mantle Cell Lymphoma

治疗流程

1

Initial Consultation

3-5 days

Submit medical records for review by our oncology team

2

Eligibility Assessment

1-2 weeks

Comprehensive evaluation to determine CAR-T candidacy

3

Cell Collection

1 day

Leukapheresis procedure to collect T-cells

4

CAR-T Manufacturing

2-4 weeks

T-cells are engineered in the lab

5

Conditioning & Infusion

1 week

Chemotherapy followed by CAR-T infusion

6

Monitoring

2-4 weeks

Close observation for side effects

常见问题

What is CAR-T cell therapy?

CAR-T (Chimeric Antigen Receptor T-cell) therapy is a type of immunotherapy where your own T-cells are collected, genetically modified to recognize and attack cancer cells, then infused back into your body.

Why is CAR-T cheaper in China?

China has developed its own CAR-T products and manufacturing capabilities, reducing costs significantly. Lower labor costs, government subsidies for biotech, and competitive pricing among hospitals also contribute to savings.

Is CAR-T in China as effective as in the US?

Yes. Chinese CAR-T products have shown comparable efficacy rates in clinical trials. Several Chinese CAR-T therapies have received NMPA approval and are being used in international clinical trials.

What are the risks of CAR-T therapy?

Common side effects include Cytokine Release Syndrome (CRS) and neurological toxicity. Our partner hospitals have experienced teams and protocols to manage these complications effectively.

准备好探索您的选择了吗?

提交您的病历资料进行免费、无义务评估。我们的医疗团队将审查您的病例并提供个性化建议。